Hyperplasia in glands with hormone excess.

Area of Science:

• Endocrinology
• Genetics
• Pathophysiology

Background:

• Five distinct syndromes present with predominantly hyperplastic endocrine glands and primary hormone excess.
• These include neonatal severe primary hyperparathyroidism (CASR mutation), congenital thyrotoxicosis (TSHR mutation), male-limited precocious puberty (LHR mutation), ovarian hyperstimulation syndrome (FSHR mutation), and familial hyperaldosteronism type IIIA (KCNJ5 mutation).

Purpose of the Study:

• To analyze the commonality of gland hyperplasia across these five syndromes.
• To compare hyperplasia with other endocrine disease stages (oversecretion and neoplasia) and identify underlying pathophysiological themes.

Main Methods:

• Comparative analysis of five hyperplastic syndromes with syndromes of predominant oversecretion and neoplasia.
• Examination of gland staging, progression to neoplastic stages, tumor multiplicity, and mutation types.

Main Results:

• Predominant hyperplasia represents a stable tissue endpoint in these five syndromes, linked to hormone excess.
• Hyperplasias show a higher propensity to progress to neoplastic stages compared to predominant oversecretions (P<0.02).
• Hyperplasias are characterized by mutations in plasma membrane-bound sensors (5/5), unlike neoplasias (3/14, P<0.002).

Conclusions:

• The grouping of these syndromes highlights hyperplasia as a distinct stage in endocrine disease progression.
• Mutations in plasma membrane-bound sensors are a shared and significant feature contributing to hyperplasia pathophysiology.
• Understanding hyperplasia pathophysiology, particularly the role of mutant sensors, is crucial for endocrine disease research.